Kymera Therapeutics (KYMR) reported a Q4 net loss Thursday of $0.88 per diluted share, wider than the loss of $0.25 a year earlier.
Analysts polled by FactSet expected a loss of $0.86.
Collaboration revenue for the quarter ended Dec. 31 was $7.4 million, down from $47.9 million a year earlier.
Analysts surveyed by FactSet expected $14.4 million.
Kymera said that as of Dec. 31, it had about $851 million in cash, cash equivalents, and investments, which it expects to provide a cash runway into mid-2027.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。